Jiménez-Vicente C, Othman J, Potter N, Jovanovic J, Runglall M, Aucken P, Barr L, O’Sullivan J, de Lavallade H, Lim M, Harrington P, Russell N, Dillon R. Blinatumomab for measurable residual disease relapse in acute myeloid leukemia with t(8;21) translocation: the BlinAML Trial. haematol [Internet]. 2020Sep.10 [cited 2026Jul.29];. Available from: https://haematologica.org/article/view/14312